| Title: |
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases |
| Authors: |
Carbone, Federico; Bodini, Giorgia; Brunacci, Matteo; Bonaventura, Aldo; Vecchiè, Alessandra; Liberale, Luca; CRESPI, MATTIA; Baldissarro, Isabella; Dallegri, Franco; Savarino, Vincenzo; Montecucco, Fabrizio; Giannini, Edoardo G |
| Contributors: |
Carbone, Federico; Bodini, Giorgia; Brunacci, Matteo; Bonaventura, Aldo; Vecchiè, Alessandra; Liberale, Luca; Crespi, Mattia; Baldissarro, Isabella; Dallegri, Franco; Savarino, Vincenzo; Montecucco, Fabrizio; Giannini, Edoardo G |
| Publisher Information: |
Wiley |
| Publication Year: |
2018 |
| Collection: |
Università degli Studi di Genova: CINECA IRIS |
| Subject Terms: |
matrix metalloproteinases; tissue inhibitor of matrix metalloproteinase-2; inflammatory bowel diseases; inflammation; monoclonal antibodies |
| Description: |
BACKGROUND: Growing evidence indicates tissue inhibitors of matrix metalloproteinases (TIMPs) as potential players in inflammatory bowel disease (IBD), but, no prospective data are available in IBD remission/relapse. MATERIAL & METHODS: In this prospective pilot study, a cohort of IBD patients (n=32) was enrolled and treated with monoclonal anti-TNF-α antibodies. Patients were clinically followed up for a median period of 54 weeks. Serum circulating levels of C-reactive protein (CRP), TIMP-1 and -2, matrix metalloproteinase (MMP)-9 and -8, myeloperoxidase (MPO) and neutrophil elastase (NE) were assessed by ELISA at enrollment and at the end of the treatment. RESULTS: The percentage (%) TIMP-2 reduction from baseline to end of treatment was independently associated with IBD remission at the end of treatment and follow-up as well. ROC curve analysis further confirmed the good prognostic accuracy of % TIMP-2 reduction over the treatment period. Conversely, no other change in inflammatory molecule concentrations was able to predict short- or long-term IBD remission. CONCLUSIONS: This study indicates TIMP-2 reduction during IBD treatment with monoclonal anti-TNF-α antibodies as a potential prognostic parameter of short and long term remission. To understand if TIMP-2 is an innocent biomarker or an active pathophysiological factor in IBD remains to be clarified. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/30011062; info:eu-repo/semantics/altIdentifier/wos/WOS:000446165100004; volume:48(10):e13002; firstpage:1; lastpage:8; numberofpages:8; journal:EUROPEAN JOURNAL OF CLINICAL INVESTIGATION; info:eu-repo/grantAgreement/EC/FP7/602114; https://hdl.handle.net/11567/927688 |
| DOI: |
10.1111/eci.13002 |
| Availability: |
https://hdl.handle.net/11567/927688; https://doi.org/10.1111/eci.13002 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.7A6C373C |
| Database: |
BASE |